Elicio Therapeutics Inc. (ELTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Elicio Therapeutics Inc. (ELTX) has a cash flow conversion efficiency ratio of -1.029x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.16 Million) by net assets ($7.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Elicio Therapeutics Inc. worth for the company's overall valuation and market capitalisation.
Elicio Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Elicio Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Elicio Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elicio Therapeutics Inc. ranked by their cash flow conversion efficiency. Explore Elicio Therapeutics Inc. cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tadir-Gan (Precision Products) 1993 Ltd
TA:TDGN
|
-0.009x |
|
Matrix Composites & Engineering Ltd
AU:MCE
|
0.147x |
|
Bever Holding NV
AS:BEVER
|
-0.017x |
|
Q.S.I Co. LTD
KQ:066310
|
0.001x |
|
Shenzhen SEG Co Ltd
SHE:200058
|
0.109x |
|
Uniflex Technology Inc
TW:3321
|
-0.087x |
|
Children’s Place Inc
NASDAQ:PLCE
|
0.508x |
|
Syntek Semiconductor Co Ltd
TWO:5302
|
0.004x |
Annual Cash Flow Conversion Efficiency for Elicio Therapeutics Inc. (2012–2025)
The table below shows the annual cash flow conversion efficiency of Elicio Therapeutics Inc. from 2012 to 2025. View ELTX stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.64 Million | $-36.95 Million | -22.587x | -789.28% |
| 2024-12-31 | $-11.31 Million | $-37.07 Million | 3.277x | +213.99% |
| 2023-12-31 | $11.37 Million | $-32.69 Million | -2.875x | -15.55% |
| 2022-12-31 | $8.91 Million | $-22.18 Million | -2.488x | -747.05% |
| 2021-12-31 | $81.51 Million | $-23.94 Million | -0.294x | -216.07% |
| 2020-12-31 | $-90.45 Million | $-22.89 Million | 0.253x | -80.87% |
| 2019-12-31 | $-18.59 Million | $-24.59 Million | 1.323x | +411.96% |
| 2018-12-31 | $18.91 Million | $-8.02 Million | -0.424x | -199.94% |
| 2013-12-31 | $4.46 Million | $1.89 Million | 0.424x | +68.83% |
| 2012-12-31 | $4.24 Million | $1.07 Million | 0.251x | -- |
About Elicio Therapeutics Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targ… Read more